Related references
Note: Only part of the references are listed.EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, CIpX and promote apoptosis of multiple tumor types including DIPG
Yiqun Zhang et al.
NEOPLASIA (2021)
A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
Sarra El-Soussi et al.
FRONTIERS IN PEDIATRICS (2021)
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
Carolin Golla et al.
CANCERS (2021)
Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
Maximilian Pruss et al.
BRITISH JOURNAL OF CANCER (2020)
Metabolic Fingerprinting on Synthetic Alloys for Medulloblastoma Diagnosis and Radiotherapy Evaluation
Jing Cao et al.
ADVANCED MATERIALS (2020)
FeOOH@Metal-Organic Framework Core-Satellite Nanocomposites for the Serum Metabolic Fingerprinting of Gynecological Cancers
Congcong Pei et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Pathology, diagnostics, and classification of medulloblastoma
Brent A. Orr
BRAIN PATHOLOGY (2020)
Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma
Lin Huang et al.
NATURE COMMUNICATIONS (2020)
Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis
Michal Hlavac et al.
CELLULAR ONCOLOGY (2019)
Medulloblastoma
Paul A. Northcott et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Jo Ishizawa et al.
CANCER CELL (2019)
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S. Chi et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Janus particles: design, preparation, and biomedical applications
H. Su et al.
MATERIALS TODAY BIO (2019)
Intratumoral activity of ONC201 in adult recurrent glioblastoma patients
Isabel Arrillaga et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013
Vishesh Khanna et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Georg Karpel-Massler et al.
NATURE COMMUNICATIONS (2017)
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
Isabel Arrillaga-Romany et al.
ONCOTARGET (2017)
TIC10/ONC201-a potential therapeutic in glioblastoma
Georg Karpel-Massler et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Florence M. G. Cavalli et al.
CANCER CELL (2017)
The Emerging Hallmarks of Cancer Metabolism
Natalya N. Pavlova et al.
CELL METABOLISM (2016)
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
Georg Karpel-Massler et al.
ONCOTARGET (2015)
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Joshua E. Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Molecular subgroups of medulloblastoma: the current consensus
Michael D. Taylor et al.
ACTA NEUROPATHOLOGICA (2012)
Optimizing cancer radiotherapy with 2-deoxy-D-glucose - Dose escalation studies in patients with glioblastoma multiforme
DH Singh et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: A French Society of Pediatric Oncology study
V Oyharcabal-Bourden et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
